BACKGROUND: SRS is the most prevalent infectious disease during the seawater rearing phase of farmed salmon in Chile and causes substantial production losses. Disease control is improved by use of a novel live attenuated vaccine alongside current interventions including good management practice, inactivated vaccines and antimicrobials. OBJECTIVES:: To estimate the economic incremental net benefit of adoption of a novel live vaccine to aid in the control of SRS in farmed Atlantic salmon in Chile. METHODS:: Partial budgeting was used to develop a static, deterministic, simulation model to estimate the net benefit of vaccination at the farm level from the perspective of the producer. The model was constructed to enable calculation of net benefit in one production cycle considering the impact of the live vaccine on selling price/kg salmon harvested and SRS-associated costs and losses – antimicrobial and non-antimicrobial treatment costs, veterinary costs, other operating costs, increased feed conversion ratio (FCR), mortality and distribution of fish weight at mortality – in worst, base and best case scenarios. The model was designed to be customisable for specific farms and their production characteristics, with default input parameter values based on field trials, expert opinion and contemporary local cost and revenue data. RESULTS:: Results are presented per 1,000 smolts entering the seawater rearing phase, with default parameter values. Adoption of the live vaccine yielded net benefit of US$152, US$6,836 and US$15,223 for worst, base and best case scenarios respectively. Net benefit was associated with increased sales from harvested biomass and reduced costs of antimicrobials and feed. One-way sensitivity analyses showed that the most influential input variables were impact of vaccination on selling price/kg fish, SRS-related mortality, cost of antimicrobials and FCR. CONCLUSIONS:: Adoption of a live vaccine against SRS in farmed Atlantic salmon in Chile can yield positive economic incremental net benefit.